U.S. drugmaker AstraZeneca and China International Capital Corp are teaming up to launch a $1 billion China-focused biotech venture fund, reported Bloomberg. The news outlet added that AstraZeneca will not be a majority investor, according to CEO Pascal Soriot.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.